share_log

Canaccord Genuity Maintains Buy on Health Catalyst, Lowers Price Target to $11

Canaccord Genuity Maintains Buy on Health Catalyst, Lowers Price Target to $11

Canaccord Genuity維持對健康催化劑的買入，將目標股價下調至11美元
Benzinga ·  02/23 22:44

Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $12 to $11.

Canaccord Genuity分析師理查德·克洛斯維持Health Catalyst（納斯達克股票代碼：HCAT）的買入並將目標股價從12美元下調至11美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論